3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Melanoma
15
Neoplasm Metastasis
12
Squamous Cell Carcinoma of Head and Neck
11
Lung Neoplasms
11
Skin Neoplasms
10
Neoplasms
9
Ovarian Neoplasms
8
Recurrence
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Urinary Bladder Neoplasms
6
Head and Neck Neoplasms
6
Carcinoma, Basal Cell
6
Breast Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Squamous Cell
5
Carcinoma, Merkel Cell
5
Carcinoma
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Mouth Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Stomach Neoplasms
3
Sarcoma
3
Mycosis Fungoides
3
Interventions
durvalumab
13
Bevacizumab
11
Nivolumab
10
tremelimumab
7
pembrolizumab
6
lenvatinib
6
fludarabine
6
Cyclophosphamide
6
atezolizumab
4
Radiosurgery
4
Cisplatin
4
toripalimab
3
relatlimab
3
Magnetic Resonance Imaging
3
Ipilimumab
3
Gemcitabine
3
X-Rays
2
Standard of Care
2
Sorafenib
2
Riluzole
2
Radiotherapy
2
Photons
2
Patient Navigation
2
Lidocaine
2
Hepatectomy
2
Dexamethasone
2
Biopsy
2
trastuzumab deruxtecan
1
tocilizumab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
cemiplimab
×
1 year
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled